Wednesday , February 19 2020
Home / zimbabwe / Northwestern scientists receive $ 3.1m grant to examine ALS drug therapies

Northwestern scientists receive $ 3.1m grant to examine ALS drug therapies

Two Northwestern University scientists have received a $ 3.1 million grant from the National Institute on Aging (NIA) to co-operate and test treatments for amyotrophic lateral sclerosis (ALS).

The grant was awarded to P. Jande Osdindler, Associate Professor of Neurology at the Faculty of Medicine at the University of Northwestern University in Heinberg and Richard B. And sciences

ALS, also known as Lou Gerrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord. There is a huge global effort to identify effective treatments.

Silver, the inventor of Lyria, previously received a United States grant for the defense of the extraction of compounds that transcend protein aggregation and then modify them for enhanced potency. Protein aggregation – when nerve cell proteins accumulate and accumulate together – is often associated with such neurodegenerative diseases as ALS, Alzheimer's and Parkinson's.

"The problem we are trying to solve is to identify the common cause of many different neurodegenerative diseases," Silverman said. "The compounds we develop originally for ALS may have broader applications for neurodegeneration."

Silverman and Ozdindler began collaborating to investigate whether these compounds and their derivatives would affect degenerative upper motor neurons in ALS. Previous research by Ozdindler has shown that degeneration of the upper motor neurons, and not just the spinal neurons, is an important contributor to ALS.

Our initial results with these compounds are quite promising and because we use upper motor neurons, our findings will have implications for other upper motor neuron diseases as well. "

P. Jande Osdindler, Associate Professor of Neurology, Northwestern University Heinberg School of Medicine

Ozdindler is able to impose upper motor neurons dying in ALS in green fluorescence.

"We can now track their responses to the compounds both in the plate and in the brain," Ozdindler said. "This has not been possible in the drug discovery field before."

Source link